Amgen, Inc. (NASDAQ:AMGN) Shares Purchased by MainStreet Investment Advisors LLC

MainStreet Investment Advisors LLC raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 193.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,866 shares of the medical research company’s stock after purchasing an additional 3,869 shares during the period. MainStreet Investment Advisors LLC’s holdings in Amgen were worth $1,189,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AMGN. Savior LLC acquired a new position in Amgen during the 4th quarter valued at about $34,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Amgen by 830.4% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,042 shares of the medical research company’s stock valued at $251,000 after purchasing an additional 930 shares during the period. Davis R M Inc. boosted its stake in Amgen by 5.6% during the 4th quarter. Davis R M Inc. now owns 7,322 shares of the medical research company’s stock valued at $1,765,000 after purchasing an additional 386 shares during the period. Global Retirement Partners LLC raised its position in shares of Amgen by 4.6% during the 4th quarter. Global Retirement Partners LLC now owns 2,573 shares of the medical research company’s stock worth $620,000 after buying an additional 112 shares in the last quarter. Finally, J.W. Cole Advisors Inc. bought a new stake in shares of Amgen during the 4th quarter worth about $1,275,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

In related news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total transaction of $100,856.75. Following the transaction, the director now directly owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $233.35, for a total transaction of $233,350.00. Following the transaction, the director now directly owns 15,636 shares in the company, valued at $3,648,660.60. The disclosure for this sale can be found here. Insiders have sold 2,425 shares of company stock worth $563,477 in the last 90 days. 0.25% of the stock is owned by company insiders.

A number of analysts have commented on AMGN shares. Morgan Stanley boosted their price target on shares of Amgen from $267.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Cfra boosted their price target on shares of Amgen from $223.00 to $259.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. BMO Capital Markets boosted their price target on shares of Amgen from $274.00 to $291.00 and gave the stock an “outperform” rating in a research report on Friday, May 1st. SunTrust Banks boosted their price target on shares of Amgen from $254.00 to $265.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, Wolfe Research started coverage on shares of Amgen in a research report on Tuesday, March 31st. They set a “market perform” rating and a $218.00 price target on the stock. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seventeen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $244.65.

Shares of AMGN stock traded up $1.65 during trading hours on Friday, reaching $226.43. 2,305,494 shares of the stock traded hands, compared to its average volume of 2,887,619. Amgen, Inc. has a 1-year low of $166.68 and a 1-year high of $244.99. The business has a fifty day moving average price of $228.36 and a 200 day moving average price of $225.14. The company has a quick ratio of 1.28, a current ratio of 1.59 and a debt-to-equity ratio of 3.16. The firm has a market capitalization of $132.23 billion, a PE ratio of 17.75, a PEG ratio of 1.92 and a beta of 0.97.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.70 by $0.47. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. During the same quarter in the previous year, the business earned $3.56 earnings per share. The firm’s revenue was up 10.9% compared to the same quarter last year. Research analysts expect that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, June 8th. Stockholders of record on Monday, May 18th will be issued a dividend of $1.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.83%. Amgen’s dividend payout ratio is currently 43.18%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is the return on assets (ROA) ratio?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.